Abstract Number: 438 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor, In A Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy In A Phase 3 Randomised Clinical Trial
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Here, we describe the efficacy and safety for adalimumab (ADA)…Abstract Number: 2234 • 2012 ACR/ARHP Annual Meeting
US Treatment Patterns of Psoriatic Arthritis Patients Newly Initiated On Etanercept or Adalimumab
Background/Purpose: Etanercept (ETN) and Adalimumab (ADA) are commonly used biologic disease-modifying antirheumatic drugs (DMARDs) for psoriatic arthritis (PsA) patients (pts). However, little is known about…Abstract Number: 995 • 2012 ACR/ARHP Annual Meeting
Genetic Effects of HLA-DRB1, IL4R, and FcγRIIb On Long-Term Treatment Responses in Patients with Early Rheumatoid Arthritis: 78-Week Results of a Phase 4 Study
Background/Purpose: Previous analyses suggested that the HLA-DRB1 shared epitope (SE), and the IL4R V50I and the FcγRIIb I232T single nucleotide polymorphisms (SNPs) affected response to…Abstract Number: 2217 • 2012 ACR/ARHP Annual Meeting
Even After Pretreatment with up to Three Biologics, Anti-TNFs Shows Effectiveness in Active Psoriatic Arthritis Patients
Background/Purpose: For the treatment of patients with psoriatic arthritis (PsA) only antiTNF biologics are licensed. Therefore, failures to anti-TNF are often switched to a different…Abstract Number: 775 • 2012 ACR/ARHP Annual Meeting
Long-Term Outcomes of Early Rheumatoid Arthritis Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach
Background/Purpose: In rheumatoid arthritis (RA), anti-TNF therapy is considered following 3-6 months of failed methotrexate (MTX) treatment. Some patients (pts), particularly those with many risk…Abstract Number: 2173 • 2012 ACR/ARHP Annual Meeting
Pharmacoeconomic Evaluation of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in Reducing Disease Activity in Patients with Rheumatoid Arthritis
Background/Purpose: ADACTA trial (Gabay C et al EULAR June 2012) showed that tocilizumab (TCZ) monotherapy was superior to adalimumab (ADA) monotherapy in reducing signs and…Abstract Number: 772 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy Compared with Adalimumab Monotherapy in Patients with Rheumatoid Arthritis: Results of a 24-Week Study
Background/Purpose: Approximately one-third of RA pts treated with biologics receive them as monotherapy (ie, without other DMARDs).1-3 Although tocilizumab (TCZ), an IL-6 receptor inhibitor, has…Abstract Number: 2160 • 2012 ACR/ARHP Annual Meeting
Fcγ Receptor IIIb Polymorphism Is Associated with Injection Reaction to Adalimumab in Patients with Rheumatoid Arthritis
Background/Purpose: Biological agents targeting a specific molecule provide an effective means for therapeutic management of rheumatoid arthritis (RA), but infusion/injection reaction is a major adverse…Abstract Number: 580 • 2012 ACR/ARHP Annual Meeting
Changes in Sclerostin, Dickkopf-1 and Serum Markers of Inflammation, Cartilage and Bone Turnover in Patients with Axial Spondyloarthritis Treated with Adalimumab
Background/Purpose: Few studies have investigated changes in plasma sclerostin and Dickkopf1 (DKK-1) in relation to other biomarkers of inflammation, cartilage and bone turnover during treatment…Abstract Number: 2010 • 2012 ACR/ARHP Annual Meeting
Administration of Routine Preventative Vaccinations in Children with Juvenile Idiopathic Arthritis Receiving Adalimumab
Background/Purpose: Adalimumab, a fully human monoclonal antibody to tumor necrosis factor-alpha (TNF) has been shown to be safe and effective in juvenile idiopathic arthritis (JIA),…Abstract Number: 568 • 2012 ACR/ARHP Annual Meeting
14-3-3 Eta Is a Modifiable Serum Biomarker That Marks Adalimumab Response in Psoriatic Arthritis
Background/Purpose: 14-3-3 eta is a synovial-derived biomarker whose serum expression is independently associated with joint damage in RA and PsA. We previously reported that 14-3-3…Abstract Number: 1973 • 2012 ACR/ARHP Annual Meeting
Effect of Adalimumab On the Serum Level of Undercarboxylated Osteocalcin (ucOC), Bone Biochemical Markers and Bone Mineral Density
Background/Purpose: The osteoporotic fracture in patients with rheumatiod arthritis (RA) is caused by systemic osteoporosis as well as periarticular osteoporosis, On the other hand, the…Abstract Number: 484 • 2012 ACR/ARHP Annual Meeting
Comparison of Rheumatoid Arthritis-Related Health Care Resource Use and Comorbidities Among Patients with Rheumatoid Arthritis Treated with Adalimumab Vs. Etanercept
Background/Purpose: Adalimumab (ADA) and etanercept (ETN) are two commonly used tumor necrosis factor (TNF)-α antagonists for the treatment of rheumatoid arthritis (RA). The study is…Abstract Number: 1829 • 2012 ACR/ARHP Annual Meeting
Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance
Background/Purpose: Tumor Necrosis Factor Inhibitors (TNFi) are the mainstay of treatment for rheumatoid arthritis (RA) in patients with moderate to severe disease. The three most…Abstract Number: 486 • 2012 ACR/ARHP Annual Meeting
Impact of Adalimumab Therapy On Laboratory Parameters of Interest in Patients with Early or Long-Standing Rheumatoid Arthritis
Background/Purpose: The systemic inflammation of rheumatoid arthritis (RA) can have detrimental effects on the hematopoietic and cardiovascular systems. Additionally, effective DMARD treatments for RA can…